Both IL-2 and bispecific antibodies that engage and activate T cells underscore the role of T cells for targeting cancers because they demonstrate that T cells can be either directed to specific antigens on tumors, or can be activated or re-activated despite what may be an immunosuppressive milieu or specific down-regulation of T cells against tumors. The gene discussed is IL2; the disease is cancer.